At least 18 federal lawsuits claiming Johnson & Johnson’s talc-based powders caused ovarian cancer could be consolidated for pretrial work, and J&J wants that litigation in New Jersey, its home state.
Another jury smacked J&J with damages in a Risperdal breast-development case. But this time, that verdict came to $70M--far more than previous verdicts in similar cases.
